Dual modifications of α-Galactosylceramide Synergize to promote activation of human invariant natural killer T cells and stimulate anti-tumor immunity

Chennamadhavuni, Divya, Saavedra-Avila, Noemi Alejandra, Carreño, Leandro J., Guberman-Pfeffer, Matthew J., Arora, Pooja, Yongqing, Tang, Koay, Hui-Fern, Godfrey, Dale I., Keshipeddy, Santosh, Richardson, Stewart K., Sundararaj, Srinivasan, Lo, Jae Ho, Wen, Xiangshu, Gascón, José A., Yuan, Weiming, Rossjohn, Jamie ORCID: https://orcid.org/0000-0002-2020-7522, Le Nours, Jérôme, Porcelli, Steven A. and Howell, Amy R. 2018. Dual modifications of α-Galactosylceramide Synergize to promote activation of human invariant natural killer T cells and stimulate anti-tumor immunity. Cell Chemical Biology 25 (5) , pp. 571-584. 10.1016/j.chembiol.2018.02.009

Preview

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (924kB) | Preview

Abstract

Glycosylceramides that activate CD1d-restricted invariant natural killer T (iNKT) cells have potential therapeutic applications for augmenting immune responses against cancer and infections. Previous studies using mouse models identified sphinganine variants of α-galactosylceramide as promising iNKT cell activators that stimulate cytokine responses with a strongly proinflammatory bias. However, the activities of sphinganine variants in mice have generally not translated well to studies of human iNKT cell responses. Here, we show that strongly proinflammatory and anti-tumor iNKT cell responses were achieved in mice by a variant of α-galactosylceramide that combines a sphinganine base with a hydrocinnamoyl ester on C6″ of the sugar. Importantly, the activities observed with this variant were largely preserved for human iNKT cell responses. Structural and in silico modeling studies provided a mechanistic basis for these findings and suggested basic principles for capturing useful properties of sphinganine analogs of synthetic iNKT cell activators in the design of immunotherapeutic agents.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Elsevier Science B.V., Amsterdam
ISSN:	2451-9456
Date of First Compliant Deposit:	30 July 2018
Date of Acceptance:	16 February 2018
Last Modified:	21 Nov 2024 02:30
URI:	https://orca.cardiff.ac.uk/id/eprint/110564

Citation Data

Cited 19 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item